A variety of factors have been considered for their possible influence on IBA1 levels in the context of AD, including APOE and TREM2 risk variants, dementia, AD histopathology, and AD Braak staging [14, 34–38]. This evidence concerns the gene TREM2 and Alzheimer disease.